Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OXYCONTIN vs CEFOTETAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and disrupting peptidoglycan cross-linking.
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate,Off-label: Treatment of opioid dependence (as part of substitution therapy)
FDA-approved: Treatment of infections caused by susceptible bacteria including lower respiratory tract infections, urinary tract infections, intra-abdominal infections, skin and skin structure infections, gynecologic infections, septicemia, and bone/joint infections.,Off-label: Surgical prophylaxis, pelvic inflammatory disease, and treatment of mixed aerobic-anaerobic infections.
10 mg orally every 12 hours; titrate based on pain severity and prior opioid exposure.
1 to 2 g intravenously or intramuscularly every 12 hours. For severe infections, up to 2 g every 12 hours for 5-10 days.
4.5-5.0 hours (immediate-release); controlled-release OXYCONTIN has an apparent half-life of 4.5-8.7 hours. Terminal half-life is ~3.5-4 hours for immediate-release, reflecting context-sensitive elimination.
3-4.5 hours (6-8 hours in renal impairment).
Oxycodone is metabolized primarily via CYP3A4 to noroxycodone (major metabolite) and via CYP2D6 to oxymorphone (minor metabolite). Both metabolites are active, with oxymorphone having higher potency. Oxycodone and its metabolites are conjugated and excreted in urine.
Not significantly metabolized; primarily excreted unchanged in urine via glomerular filtration and tubular secretion.
Primarily renal (90% as metabolites, 10% unchanged). Also biliary/fecal (10%).
Renal (80-90% unchanged), biliary (small amount, up to 20% in bile), fecal (<5%).
38-45%, primarily bound to albumin.
88-90% (primarily albumin).
2.6-3.0 L/kg. Extensive tissue distribution, high Vd indicates penetration into peripheral tissues.
8-10 L (0.13-0.16 L/kg; distributes well into tissues, including bile and peritoneal fluid).
Oral immediate-release: 60-87% (first-pass metabolism). Oral extended-release (Oxy Contin): 60-87% (similar). Intravenous: 100%.
IM: ~100%.
Cr Cl 30-60 m L/min: reduce dose by 25%; Cr Cl <30 m L/min: reduce dose by 50% and administer every 12 hours; hemodialysis: avoid use.
Cr Cl 30-50 m L/min: 1-2 g every 24 hours. Cr Cl 10-29 m L/min: 1-2 g every 48 hours. Cr Cl <10 m L/min: 1-2 g every 48 hours. Hemodialysis: Administer 25% of usual dose every 48 hours, given after dialysis.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
No specific adjustment for Child-Pugh A or B. For Child-Pugh C, use with caution and monitor for adverse effects; no established dose reduction.
Not approved for pediatric patients <18 years; for children ≥11 years (opioid-tolerant): 0.2 mg/kg orally every 12 hours, titrate; maximum single dose 10 mg.
Children 1 month to 16 years: 40-80 mg/kg/day intravenously or intramuscularly divided every 12 hours. For severe infections, up to 100 mg/kg/day. Maximum daily dose: 6 g.
Initiate at 5 mg orally every 12 hours; titrate cautiously; monitor for respiratory depression and constipation.
Use lower end of dosing range based on renal function; adjust per creatinine clearance. Monitor renal function closely.
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS
None.
Addiction, abuse, and misuse: Oxy Contin exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing, and monitor all patients regularly for the development of these behaviors or conditions.,Life-threatening respiratory depression: Serious, life-threatening, or fatal respiratory depression may occur. Monitor for respiratory depression, especially during initiation of therapy or following a dose increase. Instruct patients to swallow tablets whole; crushing, chewing, or dissolving can cause rapid release and absorption of a potentially fatal dose.,Accidental ingestion: Accidental ingestion of even one dose of Oxy Contin, especially by children, can result in a fatal overdose of oxycodone.,Neonatal opioid withdrawal syndrome: Prolonged use of Oxy Contin during pregnancy can result in withdrawal in the neonate. Neonatal opioid withdrawal syndrome, unlike opioid withdrawal in adults, may be life-threatening if not recognized and treated.,Risks from concomitant use with benzodiazepines or other CNS depressants: Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate.
Hypersensitivity reactions: Cross-allergenicity with other beta-lactams; caution in penicillin-allergic patients.,Hemolytic anemia: Reports of immune-mediated hemolytic anemia; monitor for signs of hemolysis.,Clostridioides difficile-associated diarrhea (CDAD): May cause antibiotic-associated colitis; evaluate if diarrhea occurs.,Coagulation abnormalities: May prolong prothrombin time; monitor in patients at risk for bleeding or on anticoagulants.,Renal impairment: Dose adjustment required in moderate to severe renal dysfunction.,Superinfection: Prolonged use may lead to overgrowth of nonsusceptible organisms.
Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus,Hypersensitivity (e.g., anaphylaxis) to oxycodone or any other components of the product
Hypersensitivity to cefotetan or other cephalosporins.,History of immediate hypersensitivity reactions (e.g., anaphylaxis) to penicillins or other beta-lactams (relative contraindication).
Avoid alcohol, which can increase oxycodone absorption and central nervous system depression. Grapefruit juice may alter oxycodone metabolism; limit or avoid consumption. No specific food restrictions, but high-fat meals may slow absorption slightly; take with or without food consistently.
Avoid alcohol and any products containing alcohol (e.g., beer, wine, liquor, certain mouthwashes, cough syrups, and elixirs) during cefotetan therapy and for at least 48 hours after the last dose due to risk of disulfiram-like reaction. No other significant food interactions.
FDA Pregnancy Category C prior to 2020; no adequate studies in pregnant women. First trimester: Limited data suggest possible increased risk of neural tube defects (1.8-fold) and oral clefts (1.5-fold) with opioid use, but confounded by underlying conditions. Second and third trimesters: Chronic use may cause fetal opioid dependence and neonatal abstinence syndrome (NAS); maternal withdrawal may precipitate preterm labor. Avoid prolonged use near term due to risk of neonatal respiratory depression.
Cefotetan did not cause fetal harm in animal studies at doses up to 1-2 times the human dose. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, cefotetan should be used during pregnancy only if clearly needed. The risk is considered low, but no trimester-specific data are available. It crosses the placenta and achieves therapeutic concentrations in fetal serum, amniotic fluid, and cord blood.
Oxycodone is excreted into breast milk; relative infant dose is approximately 2.7–8.8% of maternal weight-adjusted dose. M/P ratio unknown. Monitor infant for sedation, respiratory depression, and poor feeding. American Academy of Pediatrics considers oxycodone compatible with breastfeeding with caution; avoid rapid accumulation in mothers with impaired metabolism (CYP2D6 poor metabolizers).
Cefotetan is excreted into human milk in low concentrations. The milk-to-plasma ratio (M/P) is not well established; one study reported a concentration of 0.5 mcg/m L at 2 hours after a 1 g dose. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Pregnancy increases oxycodone clearance by 1.3- to 2.5-fold due to enhanced hepatic metabolism (CYP3A4 and CYP2D6 induction) and increased renal blood flow. Dose adjustments may be necessary to maintain analgesia; clinical monitoring for pain control and withdrawal symptoms is essential. Titrate to effect; avoid abrupt discontinuation. Postpartum clearance returns to baseline over 1-2 weeks.
Pharmacokinetic changes during pregnancy (increased volume of distribution, enhanced renal clearance) may alter cefotetan concentrations. However, specific dosing adjustment recommendations for pregnancy are not established. Standard adult dosing is generally used, but careful monitoring for clinical response is advised. For patients with renal impairment, dosing should be adjusted based on creatinine clearance.
Oxy Contin is an extended-release formulation of oxycodone, indicated for around-the-clock pain management. Do not crush, chew, or break tablets, as this can lead to rapid release and fatal overdose. Use with caution in patients with respiratory compromise, head injury, or increased intracranial pressure. Monitor for signs of misuse, abuse, or addiction. Abrupt discontinuation may precipitate withdrawal; taper dose gradually. Constipation is common; consider prophylactic laxatives. Contraindicated in severe asthma, paralytic ileus, or hypersensitivity.
Cefotetan is a second-generation cephalosporin with activity against Bacteroides fragilis, making it useful for mixed aerobic-anaerobic infections. It has a disulfiram-like reaction with alcohol; advise patients to avoid alcohol during therapy and for 48 hours after. Cefotetan may cause hypoprothrombinemia; monitor prothrombin time in at-risk patients and consider vitamin K prophylaxis. Dose adjustment required in renal impairment (Cr Cl < 30 m L/min). Administer by slow IV injection over 3-5 minutes or IV infusion over 30 minutes. Do not use in patients with immediate hypersensitivity to cephalosporins or severe penicillin allergy.
Take Oxy Contin exactly as prescribed, usually every 12 hours. Do not take more or less than directed.,Swallow the tablet whole with water. Do not crush, chew, or break the tablet, as this can cause a dangerous overdose.,Avoid alcohol and other central nervous system depressants (e.g., benzodiazepines, sedatives) as they increase the risk of severe sedation, respiratory depression, and death.,Do not stop taking Oxy Contin suddenly; ask your doctor how to safely discontinue the medication to avoid withdrawal symptoms.,Common side effects include constipation, nausea, drowsiness, and dizziness. Contact your doctor if you experience severe constipation, difficulty breathing, or signs of allergic reaction.,Store Oxy Contin in a secure place out of sight and reach of children and pets. Dispose of unused medication via a drug take-back program.,Do not drive or operate heavy machinery until you know how Oxy Contin affects you.,Inform all healthcare providers that you are taking Oxy Contin, especially before surgery or emergency treatment.
Take cefotetan exactly as prescribed; complete the full course even if you feel better.,Avoid alcohol and products containing alcohol during treatment and for 48 hours after the last dose to prevent severe nausea, vomiting, flushing, and headache.,Inform your doctor if you have a history of bleeding problems or are on blood thinners; cefotetan may increase bleeding risk.,Report any signs of allergic reaction: rash, itching, swelling, difficulty breathing.,If you experience diarrhea that is severe or contains blood/mucus, contact your doctor immediately; this may signal a Clostridium difficile infection.,Cefotetan may cause dizziness; avoid driving or operating machinery until you know how it affects you.,Store at room temperature; do not refrigerate reconstituted solution. Discard any unused solution after 24 hours.
No interactions on record
"The serum concentration of Probenecid can be increased when it is combined with Cefotetan."
"Acenocoumarol may increase the anticoagulant activities of Cefotetan."
"Warfarin may increase the anticoagulant activities of Cefotetan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OXYCONTIN vs CEFOTETAN, answered by our medical review team.
OXYCONTIN is a Opioid Analgesic that works by Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression.. CEFOTETAN is a Cephalosporin Antibiotic that works by Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and disrupting peptidoglycan cross-linking.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OXYCONTIN and CEFOTETAN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OXYCONTIN is: 10 mg orally every 12 hours; titrate based on pain severity and prior opioid exposure.. The standard adult dose of CEFOTETAN is: 1 to 2 g intravenously or intramuscularly every 12 hours. For severe infections, up to 2 g every 12 hours for 5-10 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OXYCONTIN and CEFOTETAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OXYCONTIN is classified as Category C. FDA Pregnancy Category C prior to 2020; no adequate studies in pregnant women. First trimester: Limited data suggest possible increased risk of neural tube defects (1.8-fold) and o. CEFOTETAN is classified as Category C. Cefotetan did not cause fetal harm in animal studies at doses up to 1-2 times the human dose. There are no adequate and well-controlled studies in pregnant women. Because animal re. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.